{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T10:13:58Z","timestamp":1788171238479,"version":"build-2803163510"},"reference-count":48,"publisher":"BioExcel","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DIC"],"abstract":"<jats:p>Graves\u2019 disease is an autoimmune disorder and represents the most prevalent cause of hyperthyroidism. Its pathogenesis involves a complex interplay of immunological mechanisms, with a central role attributed to stimulating autoantibodies directed against the thyroid- stimulating hormone receptor (TSHR) expressed on thyroid follicular cells. The differential diagnosis of hyperthyroidism is of paramount importance, including other causes of thyrotoxicosis such as autonomously functioning thyroid adenoma, toxic nodular goitre, various forms of inflammatory or destructive thyroiditis and factitious thyrotoxicosis. The cornerstone of initial therapy for Graves\u2019 disease is the administration of antithyroid drugs (ATDs), whereas radioiodine ablation and total thyroidectomy constitute important therapeutic options, primarily in cases of disease recurrence or when serious adverse events related to ATDs occur. During recent decades, prolonged low-dose ATD regimens have demonstrated comparable safety profiles whilst offering superior efficacy relative to the conventional 18-month treatment course. Emerging therapeutic approaches involve immunomodulatory strategies targeting B lymphocytes, IgG recycling pathways and TSHR itself. Furthermore, the induction of immune tolerance to TSHR represents a promising future direction. This review aims to provide a comprehensive overview of the differential diagnosis of thyrotoxicosis as well as current and evolving therapeutic strategies for the management of hyperthyroidism in Graves\u2019 disease.\n\nDownload the Plain Language Summary of this article: https:\/\/www.drugsincontext.com\/plain-language-summaries\/plain-language-summary-how-to-manage-autoimmune-hyperthyroidism-graves-disease-from-differential-diagnosis-to-emerging-immunological-therapies\n\nThis article is part of the How to manage thyroid diseases: from autoimmunity to malignancy Special Issue: https:\/\/www.drugsincontext.com\/special_issues\/how-to-manage-thyroid-diseases-from-autoimmunity-to-malignancy<\/jats:p>","DOI":"10.7573\/dic.2026-4-10","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T09:17:27Z","timestamp":1788167847000},"page":"1","source":"Crossref","is-referenced-by-count":0,"title":["How to manage autoimmune hyperthyroidism (Graves\u2019 disease): from differential diagnosis to emerging immunological therapies"],"prefix":"10.7573","author":[{"given":"Olga","family":"Karapanou","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00y1kmp77","id-type":"ROR","asserted-by":"publisher"}],"name":"NIMTS Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"Saltiki","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04gnjpq42","id-type":"ROR","asserted-by":"publisher"}],"name":"National and Kapodistrian University of Athens"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios K","family":"Markantes","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/017wvtq80","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Patras"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Kasotas","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01s5dt366","id-type":"ROR","asserted-by":"publisher"}],"name":"University Hospital of Larissa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Michalaki","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/017wvtq80","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Patras"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grigoris","family":"Effraimidis","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01s5dt366","id-type":"ROR","asserted-by":"publisher"}],"name":"University Hospital of Larissa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10047","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"1.\tTaylor PN, Albrecht D, Scholz A, et al. Global epidemiology of hyperthyroidism and hypothyroidism. Nat Rev Endocrinol. 2018;14(5):301\u2013316. https:\/\/doi.org\/10.1038\/nrendo.2018.18","DOI":"10.1038\/nrendo.2018.18"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"2.\tChen J, Zhang L, Zhang X. Overall, sex-and race\/ethnicity-specific prevalence of thyroid dysfunction in US adolescents aged 12\u201318 years. Front Public Health. 2024;12:1366485. https:\/\/doi.org\/10.3389\/fpubh.2024.1366485","DOI":"10.3389\/fpubh.2024.1366485"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"3.\tMcLeod DS, Caturegli P, Cooper DS, Matos PG, Hutfless S. Variation in rates of autoimmune thyroid disease by race\/ ethnicity in US military personnel. JAMA. 2014;311(15):1563\u20131565. https:\/\/doi.org\/10.1001\/jama.2013.285606","DOI":"10.1001\/jama.2013.285606"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"4.\tWiersinga WM, Poppe KG, Effraimidis G. Hyperthyroidism: aetiology, pathogenesis, diagnosis, management, complications, and prognosis. Lancet Diabetes Endocrinol. 2023;11(4):282\u2013298. https:\/\/doi.org\/10.1016\/S2213- 8587(23)00005-0","DOI":"10.1016\/S2213-8587(23)00005-0"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"5.\tRoss DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26(10):1343\u20131421. https:\/\/doi.org\/10.1089\/ thy.2016.0229","DOI":"10.1089\/thy.2016.0229"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"6.\tFranklyn JA, Boelaert K. Thyrotoxicosis. Lancet. 2012;379(9821):1155\u20131166. https:\/\/doi.org\/10.1016\/S0140- 6736(11)60782-4","DOI":"10.1016\/S0140-6736(11)60782-4"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"7.\tSawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med. 1994;331(19):1249\u20131252. https:\/\/doi.org\/10.1056\/NEJM199411103311901","DOI":"10.1056\/NEJM199411103311901"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"8.\tBoelaert K, Torlinska B, Holder RL, Franklyn JA. Older subjects with hyperthyroidism present with a paucity of symptoms and signs: a large cross-sectional study. J Clin Endocrinol Metab. 2010;95(6):2715\u20132726. https:\/\/doi.org\/ 10.1210\/jc.2009-2495","DOI":"10.1210\/jc.2009-2495"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"9.\tGoichot B, Caron P, Landron F, Bouee S. Clinical presentation of hyperthyroidism in a large representative sample of outpatients in France: relationships with age, aetiology and hormonal parameters. Clin Endocrinol. 2016;84(3):445\u2013451. https:\/\/doi.org\/10.1111\/cen.12816","DOI":"10.1111\/cen.12816"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"10.\tKahaly GJ, Bartalena L, Hegedus L, Leenhardt L, Poppe K, Pearce SH. 2018 European Thyroid association guideline for the management of Graves\u2019 hyperthyroidism. Eur Thyroid J. 2018;7(4):167\u2013186. https:\/\/doi.org\/10.1159\/000490384","DOI":"10.1159\/000490384"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"11.\tWiersinga WM, Eckstein AK, \u017darkovi\u0107 M. Thyroid eye disease (Graves\u2019 orbitopathy): clinical presentation, epidemiology, pathogenesis, and management. Lancet Diabetes Endocrinol. 2025;13(7):600\u2013614. https:\/\/doi.org\/ 10.1016\/s2213-8587(25)00066-x","DOI":"10.1016\/S2213-8587(25)00066-X"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"12.\tGoichot B, Lefebvre F, Vinzio S, et al. Treatment of subclinical hyperthyroidism in patients older than 50 years: a randomized controlled study. Eur Thyroid J. 2024;13(6):e240121. https:\/\/doi.org\/10.1530\/ETJ-24-0121","DOI":"10.1530\/ETJ-24-0121"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"13.\tKahaly GJ, Diana T, Olivo PD. Tsh receptor antibodies: relevance & utility. Endocr Pract. 2020;26(1):97\u2013106. https:\/\/doi. org\/10.4158\/EP-2019-0363","DOI":"10.4158\/EP-2019-0363"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"14.\tBeck-Peccoz P, Lania A, Beckers A, Chatterjee K, Wemeau JL. 2013 European thyroid association guidelines for the diagnosis and treatment of thyrotropin-secreting pituitary tumors. Eur Thyroid J. 2013;2(2):76\u201382. https:\/\/doi.org\/ 10.1159\/000351007","DOI":"10.1159\/000351007"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"15.\tPappa T, Refetoff S. Resistance to thyroid hormone beta: a focused review. Front Endocrinol. 2021;12:656551. https:\/\/ doi.org\/10.3389\/fendo.2021.656551","DOI":"10.3389\/fendo.2021.656551"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"16.\tKurita S, Sakurai M, Kita Y, et al. Measurement of thyroid blood flow area is useful for diagnosing the cause of thyrotoxicosis. Thyroid. 2005;15(11):1249\u20131252. https:\/\/doi.org\/10.1089\/thy.2005.15.1249","DOI":"10.1089\/thy.2005.15.1249"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"17.\tZarkovic M, Wiersinga W, Perros P, et al. Antithyroid drugs in Graves\u2019 hyperthyroidism: differences between \u201cblock and replace\u201d and \u201ctitration\u201d regimes in frequency of euthyroidism and Graves\u2019 orbitopathy during treatment. J Endocrinol Invest. 2021;44(2):371\u2013378. https:\/\/doi.org\/10.1007\/s40618-020-01320-7","DOI":"10.1007\/s40618-020-01320-7"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"18.\tAbraham P, Avenell A, McGeoch SC, Clark LF, Bevan JS. Antithyroid drug regimen for treating Graves\u2019 hyperthyroidism. Cochrane Database Syst Rev. 2010(4):CD003420. https:\/\/doi.org\/10.1002\/14651858.CD003420.pub4","DOI":"10.1002\/14651858.CD003420.pub4"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"19.\tVos XG, Endert E, Zwinderman AH, Tijssen JG, Wiersinga WM. Predicting the risk of recurrence before the start of antithyroid drug therapy in patients with Graves\u2019 hyperthyroidism. J Clin Endocrinol Metab. 2016;101(4):1381\u20131389. https:\/\/doi.org\/10.1210\/jc.2015-3644","DOI":"10.1210\/jc.2015-3644"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"20.\tAzizi F, Amouzegar A, Tohidi M, et al. Increased remission rates after long-term methimazole therapy in patients with Graves\u2019 disease: results of a randomized clinical trial. Thyroid. 2019;29(9):1192-1200. https:\/\/doi.org\/10.1089\/ thy.2019.0180","DOI":"10.1089\/thy.2019.0180"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"21.\tAzizi F, Amouzegar A, Khalili D, et al. Risk of recurrence at the time of withdrawal of short- or long-term methimazole therapy in patients with Graves\u2019 hyperthyroidism: a randomized trial and a risk-scoring model. Endocrine. 2024;84(2):577\u2013588. https:\/\/doi.org\/10.1007\/s12020-023-03656-5","DOI":"10.1007\/s12020-023-03656-5"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"22.\tEl Fassi D, Nielsen CH, Bonnema SJ, Hasselbalch HC, Heged\u00fcs L. B lymphocyte depletion with the monoclonal antibody rituximab in Graves\u2019 disease: a controlled pilot study. J Clin Endocrinol Metab. 2007;92(5):1769\u20131772. https:\/\/doi.org\/10.1210\/jc.2006-2388","DOI":"10.1210\/jc.2006-2388"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"23.\tEl Fassi D, Banga JP, Gilbert JA, Padoa C, Hegedus L, Nielsen CH. Treatment of Graves\u2019 disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies. Clin Immunol. 2009;130(3):252\u2013258. https:\/\/doi.org\/10.1016\/j.clim.2008.09.007","DOI":"10.1016\/j.clim.2008.09.007"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"24.\tSalvi M, Vannucchi G, Campi I, et al. Treatment of Graves\u2019 disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. Eur J Endocrinol. 2007;156(1):33\u201340. https:\/\/doi.org\/ 10.1530\/eje.1.02325","DOI":"10.1530\/eje.1.02325"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"25.\tCheetham TD, Cole M, Abinun M, et al. Adjuvant rituximab-exploratory trial in young people with Graves disease. J Clin Endocrinol Metab. 2022;107(3):743\u2013754. https:\/\/doi.org\/10.1210\/clinem\/dgab763","DOI":"10.1210\/clinem\/dgab763"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"26.\tLeandro MJ, Cambridge G, Ehrenstein MR, Edwards JC. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54(2):613\u2013620. https:\/\/doi.org\/10.1002\/art.21617","DOI":"10.1002\/art.21617"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"27.\tKustrimovic N, Gallo D, Piantanida E, et al. Regulatory T cells in the pathogenesis of Graves\u2019 disease. Int J Mol Sci. 2023;24(22):16432. https:\/\/doi.org\/10.3390\/ijms242216432","DOI":"10.3390\/ijms242216432"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"28.\tSmith TJ, Hegedus L. Graves\u2019 disease. N Engl J Med. 2016;375(16):1552\u20131565. https:\/\/doi.org\/10.1056\/NEJMra1510030","DOI":"10.1056\/NEJMra1510030"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"29.\tFaustino LC, Kahaly GJ, Frommer L, Concepcion E, Stefan-Lifshitz M, Tomer Y. Precision medicine in Graves\u2019 disease: CD40 gene variants predict clinical response to an anti-CD40 monoclonal antibody. Front Endocrinol. 2021;12:691781. https:\/\/doi.org\/10.3389\/fendo.2021.691781","DOI":"10.3389\/fendo.2021.691781"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"30.\tRamdani Y, Lamamy J, Watier H, Gouilleux-Gruart V. Monoclonal antibody engineering and design to modulate FcRn activities: a comprehensive review. Int J Mol Sci. 2022;23(17):9604. https:\/\/doi.org\/10.3390\/ijms23179604","DOI":"10.3390\/ijms23179604"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"31.\tXavier NF, Lucena DT, Cruz AAV. Monoclonal antibodies for the treatment of Graves orbitopathy: precision medicine? Ophthalmic plast reconstr surg. 2023;39(4):307\u2013315. https:\/\/doi.org\/10.1097\/iop.0000000000002315","DOI":"10.1097\/IOP.0000000000002315"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"32.\tSalvi M, Covelli D. B cells in Graves\u2019 orbitopathy: more than just a source of antibodies? Eye. 2019;33(2):230\u2013234. https:\/\/doi.org\/10.1038\/s41433-018-0285-y","DOI":"10.1038\/s41433-018-0285-y"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"33.\tKamboj A, Harrison AR, Mokhtarzadeh A. Emerging therapies in the medical management of thyroid eye disease. Front Ophthalmol. 2023;3:1295902. https:\/\/doi.org\/10.3389\/fopht.2023.1295902","DOI":"10.3389\/fopht.2023.1295902"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"34.\tKahaly GJ, Dolman PJ, Wolf J, et al. Proof-of-concept and randomized, placebo-controlled trials of an FcRn inhibitor, batoclimab, for thyroid eye disease. J Clin Endocrinol Metab. 2023;108(12):3122\u20133134. https:\/\/doi.org\/10.1210\/ clinem\/dgad381","DOI":"10.1210\/clinem\/dgad381"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"35.\tLee ACH, Kahaly GJ. Targeted immunotherapies for Graves\u2019 thyroidal & orbital diseases. Front Immunol. 2025;16:1571427. https:\/\/doi.org\/10.3389\/fimmu.2025.1571427","DOI":"10.3389\/fimmu.2025.1571427"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"36.\tHoward JF Jr, Bril V, Vu T, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2021;20(7):526\u2013536. https:\/\/doi.org\/10.1016\/s1474-4422(21)00159-9","DOI":"10.1016\/S1474-4422(21)00159-9"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"37.\tBril V, Dru\u017cd\u017c A, Grosskreutz J, et al. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study. Lancet Neurol. 2023;22(5):383\u2013394. https:\/\/doi.org\/10.1016\/s1474-4422(23)00077-7","DOI":"10.1016\/S1474-4422(23)00077-7"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"38.\tHoward JF Jr, Bril V, Vu T, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2021;20(7):526\u2013536. https:\/\/doi.org\/10.1016\/S1474-4422(21)00159-9","DOI":"10.1016\/S1474-4422(21)00159-9"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"39.\tStan MN, Dosiou C. The evolving therapeutic landscape of Graves\u2019 disease in adults: present and future. Eur Thyroid J. 2025;14(4):e250078. https:\/\/doi.org\/10.1530\/ETJ-25-0078","DOI":"10.1530\/ETJ-25-0078"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"40.\tMarcinkowski P, Hoyer I, Specker E, et al. A new highly thyrotropin receptor-selective small-molecule antagonist with potential for the treatment of Graves\u2019 orbitopathy. Thyroid. 2019;29(1):111\u2013123. https:\/\/doi.org\/10.1089\/ thy.2018.0349","DOI":"10.1089\/thy.2018.0349"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"41.\tSmith BR, Sanders J, Furmaniak J. TSH receptor antibodies. Thyroid. 2007;17(10):923\u2013938. https:\/\/doi.org\/10.1089\/ thy.2007.0239","DOI":"10.1089\/thy.2007.0239"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"42.\tLatif R, Realubit RB, Karan C, Mezei M, Davies TF. TSH receptor signaling abrogation by a novel small molecule. Front Endocrinol. 2016;7:130. https:\/\/doi.org\/10.3389\/fendo.2016.00130","DOI":"10.3389\/fendo.2016.00130"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"43.\tFurmaniak J, Sanders J, Sanders P, Li Y, Rees Smith B. TSH receptor specific monoclonal autoantibody K1-70(TM) targeting of the TSH receptor in subjects with Graves\u2019 disease and Graves\u2019 orbitopathy \u2013 results from a phase I clinical trial. Clin Endocrinol. 2022;96(6):878\u2013887. https:\/\/doi.org\/10.1111\/cen.14681","DOI":"10.1111\/cen.14681"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"44.\tStreeter HB, Rigden R, Martin KF, Scolding NJ, Wraith DC. Preclinical development and first-in-human study of ATX-MS-1467 for immunotherapy of MS. Neurol Neuroimmunol Neuroinflamm. 2015;2(3):e93. https:\/\/doi.org\/10.1212\/ NXI.0000000000000093","DOI":"10.1212\/NXI.0000000000000093"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"45.\tPearce SHS, Dayan C, Wraith DC, et al. Antigen-specific immunotherapy with thyrotropin receptor peptides in Graves\u2019 hyperthyroidism: a phase i study. Thyroid. 2019;29(7):1003\u20131011. https:\/\/doi.org\/10.1089\/thy.2019.0036","DOI":"10.1089\/thy.2019.0036"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"46.\tXie P, Shen L, Peng R, et al. Effects of low-dose methotrexate with methimazole in patients with Graves\u2019 disease: results of a randomized clinical trial. J Clin Endocrinol Metab. 2025;110(2):489\u2013497. https:\/\/doi.org\/10.1210\/clinem\/ dgae472","DOI":"10.1210\/clinem\/dgae472"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"47.\tAllam MM, El-Zawawy HT, Kader Okda AA, Ali Alshaikh A, Ghazy RM. Azathioprine as an adjuvant therapy in severe Graves\u2019 disease: a randomized controlled open-label clinical trial. Front Endocrinol. 2023;14:1168936. https:\/\/doi.org\/ 10.3389\/fendo.2023.1168936","DOI":"10.3389\/fendo.2023.1168936"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"48.\tLe Moli R, Malandrino P, Russo M, et al. Corticosteroid pulse therapy for Graves\u2019 ophthalmopathy reduces the relapse rate of Graves\u2019 hyperthyroidism. Front Endocrinol. 2020;11:367. https:\/\/doi.org\/10.3389\/fendo.2020.00367","DOI":"10.3389\/fendo.2020.00367"}],"container-title":["Drugs in Context"],"original-title":[],"link":[{"URL":"https:\/\/www.drugsincontext.com\/wp-content\/uploads\/2026\/08\/dic.2026-4-10.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T09:17:37Z","timestamp":1788167857000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.drugsincontext.com\/how-to-manage-autoimmune-hyperthyroidism-graves-disease-from-differential-diagnosis-to-emerging-immunological-therapies"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":48,"URL":"https:\/\/doi.org\/10.7573\/dic.2026-4-10","relation":{},"ISSN":["1740-4398","1740-4398"],"issn-type":[{"value":"1740-4398","type":"print"},{"value":"1740-4398","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]},"article-number":"dic.2026-4-10"}}